Conduit Pharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative therapies for unmet medical needs, particularly in the fields of oncology and autoimmune diseases. The company leverages its expertise in drug formulation and delivery to create targeted treatment options that aim to improve patient outcomes and quality of life. By emphasizing research and development, Conduit seeks to advance its pipeline of product candidates through various stages of clinical trials, with the ultimate goal of bringing new therapies to market that address critical health challenges faced by patients. Read More
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
Let's delve into the US markets on Wednesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
Looking for insights into the US markets one hour before the close of the markets on Tuesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top gainers and losers in today's session.
Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session.
The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit" or the “Company”) today announce that it intends to change its name to CDT Equity Inc. (“CDT”) reflecting the evolution of its strategy as a data-driven biotech development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. Originally established as Conduit Pharmaceuticals, the company has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel therapeutic treatments.
NAPLES, Fla. and CAMBRIDGE, United Kingdom, July 08, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”) today announced that it has engaged a third-party consultant to evaluate and advise on the potential adoption of a part cryptocurrency treasury reserve strategy. This initiative is designed to better inform the Company on current cryptocurrency market dynamics and support a broader capital diversification framework aligned with innovation and digital asset trends.
NAPLES, Fla. and CAMBRIDGE, United Kingdom, July 07, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit" or the “Company”) today announces the filing of four new patent applications relating to its key assets AZD1656 and AZD5658, including the Company’s first patent filings for AZD5658. These filings represent a significant expansion of Conduit’s intellectual property portfolio, further supporting its strategy to advance and license differentiated, IP-rich pharmaceutical assets.
